-
Mashup Score: 0Breast/GYN Oncology Journal Club | July 5, 2023 - 9 month(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Breast/GYN Oncology Journal Club | June 7, 2023 - 10 month(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Breast/GYN Oncology Journal Club | April 5, 2023 - 12 month(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall survival (OS) benefit in the phase III MONALEESA-7 trial of pre-/perimenopausal patients with hormone receptor (HR)-positive (HR[+] ), …
Source: PubMed Central (PMC)Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 9
Ocular adverse events are common to many antineoplastic agents, although often misunderstood. In most cases, they are easily manageable, but sometimes they require instrumental diagnostics and specific treatments. There are currently no international guidelines for the management of these toxicities. In this review we summarized the main ocular adverse events related to the antineoplastic agents…
Source: Clinical Breast CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Breast/GYN Oncology Journal Club | March 1, 2023 - 1 year(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Working… This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again. The value you provided must be within the suggested range The value you provided is outside the suggested range This…
Source: redcap.lifespan.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Breast/GYN Oncology Journal Club | February 1, 2023 - 1 year(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
The FDA has approved Guardant 360 CDx as a companion diagnostic for elacestrant in patients with ESR1-mutant, estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.
Source: Cancer NetworkCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0About Herbs App - 1 year(s) ago
The About Herbs mobile app provides you with comprehensive, objective information about herbs, botanicals, supplements, complementary therapies, and more.
Categories: Hem/Oncs, Latest HeadlinesTweet
Here’s the CME link for tonight’s #BrownJC 👉🏻 https://t.co/FN5EUPRfoM